AGI Therapeutics plc Announces First Patient Dosed in Phase II Trial of AGI-004 in Chemotherapy-induced Diarrhoea

Dublin, Ireland, February 5th 2008 - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that the first patient has been dosed in its Phase II study of AGI-004 in the treatment of chemotherapy-induced diarrhoea (CID).
MORE ON THIS TOPIC